Full-Time

Account Manager

Confirmed live in the last 24 hours

Deadline 8/29/25
Alcon

Alcon

10,001+ employees

Specializes in eye care products and solutions

No salary listed

Junior, Mid

Woodridge, IL, USA

Hybrid

Ideal candidates will live in Bolingbrook, Naperville, Aurora, IL area.

Category
Field Sales
Sales & Account Management
Requirements
  • Bachelor’s Degree or equivalent years of directly related experience (or high school +10 yrs.; Assoc.+6 yrs.)
  • 2 years related selling experience in medical device sales, medical sales, or business to business sales
  • The ability to fluently read, write, understand, and communicate in English
Responsibilities
  • Develop and grow relationships while executing strategic plans.
  • Set clear objectives for each sales interaction based on the needs of decision makers and influencers within the account.
  • Work collaboratively with colleagues to create executional plans to help meet customer and organization needs.
  • Execute marketing plan for specific products to help change customer behavior, driving adoption of product.

Alcon specializes in eye care products and vision solutions aimed at improving people's eyesight and overall quality of life. Their product offerings include solutions for cataract surgery, retinal health, and contact lenses. Alcon's products work by utilizing advanced technology and research to provide effective treatments and aids for various eye conditions. What sets Alcon apart from its competitors is its strong emphasis on research and development, ensuring that they remain leaders in the eye care industry. Additionally, Alcon is dedicated to fostering a diverse and inclusive workplace, which is reflected in their corporate culture. The company's goal is to enhance vision and eye health for individuals worldwide while maintaining a commitment to innovation and inclusivity.

Company Size

10,001+

Company Stage

IPO

Headquarters

Geneva, Switzerland

Founded

1945

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing myopia prevalence boosts demand for Alcon's innovative contact lens solutions.
  • FDA approval of Acoltremon Ophthalmic Solution expands Alcon's product portfolio for dry eye disease.
  • Digital health trends offer Alcon opportunities to integrate advanced tools into eye care.

What critics are saying

  • Increased competition from emerging companies may impact Alcon's market share.
  • Patent litigation with Padagis Israel Pharms. Ltd. could lead to financial liabilities.
  • LumiThera acquisition may face integration challenges, affecting operational efficiency.

What makes Alcon unique

  • Alcon leads in eye care with innovative cataract and retinal health solutions.
  • Their commitment to diversity and inclusion strengthens their corporate culture and values.
  • Alcon's strategic acquisitions, like LumiThera, enhance their product offerings and market position.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

HSA Medical Plan

PTO

Paid Parental leave

401k

Retirement Plan Company Contribution

Low payroll deductions

Tuition Reimbursement Program

Annual Bonus

Free Family Contact Lens Program

12 Company Paid Holidays

Company News

Opti-Guide
Jul 8th, 2025
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

Alcon announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.

Optics.org
Jul 8th, 2025
Alcon snaps up LumiThera for light-based AMD treatment

Alcon, the Geneva-headquartered eyecare company, has announced plans to acquire LumiThera, a US firm that is working on a multi-wavelength treatment for dry age-related macular degeneration (AMD).

Alcon
Jul 8th, 2025
Alcon Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises

FORT WORTH, July 8, 2025 - Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Julie M. Brewer will join the company and its Executive Leadership Team as Senior Vice President, President, Global Franchises, effective July 9.

Ophthalmology Times
Jul 7th, 2025
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Alcon is continuing its trend of acquisitions in 2025 with the recent announcement that the company will acquire LumiThera, Inc. and its photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD).

HCPLive
May 29th, 2025
FDA Approves Acoltremon Ophthalmic Solution (TRYPTYR) for Dry Eye Disease

Alcon has also announced its intention to launch acoltremon ophthalmic solution in the US during the third quarter of 2025 and anticipates bringing it to other markets in the future.